ArticleStem cell research & therapy2011
Successful disease-specific induced pluripotent stem cell generation from patients with kidney transplantation.
Article in Stem cell research & therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 63 citations in OpenAlex.
- Lupus Heart Disease Modeling with Combination of Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Lupus Patient Serum.International journal of stem cells · 2022Article
- Stem Cell-Derived Extracellular Vesicles as Potential Therapeutic Approach for Acute Kidney Injury.Frontiers in immunology · 2022Review
- GDNF drives rapid tubule morphogenesis in a novel 3DJournal of cell science · 2020Article
- An Overview of In Vivo and In Vitro Models for Autosomal Dominant Polycystic Kidney Disease: A Journey from 3D-Cysts to Mini-Pigs.International journal of molecular sciences · 2020Review
- Cystic renal-epithelial derived induced pluripotent stem cells from polycystic kidney disease patients.Stem cells translational medicine · 2020Article
- Stem Cell Therapies in Kidney Diseases: Progress and Challenges.International journal of molecular sciences · 2019Review
- Multi-omic analysis of signalling factors in inflammatory comorbidities.BMC bioinformatics · 2018Article
- Engineered Kidney Tubules for Modeling Patient-Specific Diseases and Drug Discovery.EBioMedicine · 2018Article
- Generation of special autosomal dominant polycystic kidney disease iPSCs with the capability of functional kidney-like cell differentiation.Stem cell research & therapy · 2017Article
- Regenerative Medicine, Disease Modeling, and Drug Discovery in Human Pluripotent Stem Cell-derived Kidney Tissue.European Medical Journal. Reproductive health · 2017Article
- Modeling Cancer with Pluripotent Stem Cells.Trends in cancer · 2016Review
- hiPSC-derived iMSCs: NextGen MSCs as an advanced therapeutically active cell resource for regenerative medicine.Journal of cellular and molecular medicine · 2016Review
- Urine-derived induced pluripotent stem cells as a modeling tool to study rare human diseases.Intractable & rare diseases research · 2016Review
- Integrated analysis of mRNA, microRNA and protein in systemic lupus erythematosus-specific induced pluripotent stem cells from urine.BMC genomics · 2016Article
- Recent Progress in Stem Cell Therapy for Diabetic Nephropathy.Kidney diseases (Basel, Switzerland) · 2016Review
- Comparison of stem cell therapies for acute kidney injury.American journal of stem cells · 2016Review
- iPS cell technology: Future impact on renal care.Nephrology news & issues · 2015Article
- From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Review
- Modeling Kidney Disease with iPS Cells.Biomarker insights · 2015Review
- Directed differentiation of pluripotent stem cells to kidney cells.Seminars in nephrology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
introductionEnd-stage renal disease (ESRD) is a major public health problem. Although kidney transplantation is a viable therapeutic option, this therapy is associated with significant limitations, including a shortage of donor organs. Induced pluripotent stem (iPS) cell technology, which allows derivation of patient-specific pluripotent stem cells, could provide a possible alternative modality for kidney replacement therapy for patients with ESRD.
methodsThe feasibility of iPS cell generation from patients with a history of ESRD was investigated using lentiviral vectors expressing pluripotency-associated factors.
resultsIn the present article we report, for the first time, generation of iPS cells from kidney transplant recipients with a history of autosomal-dominant polycystic kidney disease (ADPKD), systemic lupus erythematosus, or Wilms tumor and ESRD. Lentiviral transduction of OCT4, SOX2, KLF4 and c-MYC, under feeder-free conditions, resulted in reprogramming of skin-derived keratinocytes. Keratinocyte-derived iPS cells exhibited properties of human embryonic stem cells, including morphology, growth properties, expression of pluripotency genes and surface markers, spontaneous differentiation and teratoma formation. All iPS cell clones from the ADPKD patient retained the conserved W3842X mutation in exon 41 of the PKD1 gene.
conclusionsOur results demonstrate successful iPS cell generation from patients with a history of ESRD, PKD1 gene mutation, or chronic immunosuppression. iPS cells from autosomal kidney diseases, such as ADPKD, would provide unique opportunities to study patient-specific disease pathogenesis in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.